A Study of the Efficacy and Safety of Ziprasidone for the Treatment of Acute Exacerbation of Schizophrenia or Schizoaffective Disorder

PHASE4CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

October 31, 2003

Study Completion Date

May 31, 2005

Conditions
SchizophreniaSchizoaffective Disorder
Interventions
DRUG

Ziprasidone

IM ziprasidone at an initial dose of 10 or 20 mg for the first 3 days; additional doses could be administered according to clinical need, with the maximum total daily IM dose of 40 mg. On Day 4, IM treatment was switched to oral (PO) treatment at an initial dose of 40 mg twice daily for the first 2 days; doses could be subsequently adjusted within the range of 40 to 80 mg twice daily. Total treatment duration was 6 weeks.

Trial Locations (4)

14050

Pfizer Investigational Site, Mexico City

14269

Pfizer Investigational Site, Mexico D F

14420

Pfizer Investigational Site, DF

64800

Pfizer Investigational Site, Monterrey

All Listed Sponsors
lead

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

INDUSTRY

NCT00650429 - A Study of the Efficacy and Safety of Ziprasidone for the Treatment of Acute Exacerbation of Schizophrenia or Schizoaffective Disorder | Biotech Hunter | Biotech Hunter